| Dr Jerry Z Ainsworth, MD | |
|
222 Tongass Dr, Sitka, AK 99835-9416 | |
| (907) 966-2411 | |
| (907) 966-8606 |
| Full Name | Dr Jerry Z Ainsworth |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Location | 222 Tongass Dr, Sitka, Alaska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003893611 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 3944 (Alaska) | Primary |
| Entity Name | Southeast Alaska Regional Health Consortium |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376758037 PECOS PAC ID: 1456265362 Enrollment ID: O20031114000631 |
News Archive
Grand Challenges Canada, funded by the Government of Canada, and the Grand Challenges India initiative of the Department of Biotechnology, Government of India, today announced an investment of $2.5 million (CAD) in five health innovations in India.
Cell Biosciences, Inc. and Alpha Innotech Corp. today announced that they have entered into a definitive agreement providing for the acquisition of Alpha Innotech by Cell Biosciences for $1.50 per share, or approximately $17.9 million in cash.
According to results from a new clinical trial, an experimental cancer drug regorafenib appears to extend survival slightly in patients with metastatic colorectal cancer. Regorafenib is a so-called multikinase inhibitor, which targets several of the ways cancer develops and grows, researchers said.
Patients with prostate cancer and hereditary mutations in the BRCA2 gene have a worse prognosis and lower survival rates than do the rest of the patients with the disease.
A combination of esophageal brushing and extensive genetic sequencing of the sample collected can detect chromosome alterations in people with Barrett's Esophagus, identifying patients at risk for progressing to esophageal cancer, according to a new study by researchers at the Johns Hopkins Kimmel Cancer Center and Case Western Reserve University.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jerry Z Ainsworth, MD 222 Tongass Dr, Sitka, AK 99835-9416 Ph: (907) 966-2411 | Dr Jerry Z Ainsworth, MD 222 Tongass Dr, Sitka, AK 99835-9416 Ph: (907) 966-2411 |
News Archive
Grand Challenges Canada, funded by the Government of Canada, and the Grand Challenges India initiative of the Department of Biotechnology, Government of India, today announced an investment of $2.5 million (CAD) in five health innovations in India.
Cell Biosciences, Inc. and Alpha Innotech Corp. today announced that they have entered into a definitive agreement providing for the acquisition of Alpha Innotech by Cell Biosciences for $1.50 per share, or approximately $17.9 million in cash.
According to results from a new clinical trial, an experimental cancer drug regorafenib appears to extend survival slightly in patients with metastatic colorectal cancer. Regorafenib is a so-called multikinase inhibitor, which targets several of the ways cancer develops and grows, researchers said.
Patients with prostate cancer and hereditary mutations in the BRCA2 gene have a worse prognosis and lower survival rates than do the rest of the patients with the disease.
A combination of esophageal brushing and extensive genetic sequencing of the sample collected can detect chromosome alterations in people with Barrett's Esophagus, identifying patients at risk for progressing to esophageal cancer, according to a new study by researchers at the Johns Hopkins Kimmel Cancer Center and Case Western Reserve University.
› Verified 1 days ago